Vistagen therapeutics stock
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.VistaGen Therapeutics Inc chart This market's chart. This is a visual representation of the price action in the market, over a certain period of time. You can use this to help gauge a …
Did you know?
3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and …Stock Price Forecast The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00.There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VistaGen Therapeutics (VTGN – Research Repo...According to data from Benzinga Pro, VistaGen Therapeutics shares were up 17.6%, trading at $0.16 at the time of publication. The stock has a 52-week high of $1.79 and a 52-week low of $0.08.Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ...Nov 15, 2022 · The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ... Subsidiaries VistaGen Therapeutics, Inc., a California corporation d/b/a VistaStem (VistaStem), is our wholly owned subsidiary. For the relevant periods, our Consolidated Financial Statements in this Quarterly Report on Form 10-Q (Report) ... Stock-based compensation expense for the quarter ended December 31, ...VistaGen Therapeutics Inc stock price live 3.650, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote.Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the first quarter of 2024.Find the latest Vistagen Therapeutics, Inc. (VTGN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. According to 2 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 526.87% from the latest price.
VistaGen Therapeutics on Monday posted positive topline data from the Phase III PALISADE-2 trial, showing that its investigational nasal spray fasedienol met its primary endpoint, strongly easing distress among patients with social anxiety disorder. The market reacted enthusiastically to the news, sending VistaGen’s stock soaring around …5 hours ago · William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ... Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the …VistaGen Therapeutics stock news, updates & related news. Find out why VistaGen Therapeutics's (VTGN) news sentiment is 12.96% more negative in relation to ...
Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ...SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of …Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol (PH94B) nasal ……
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Mentioned in this article. Vistagen Thera. Possible cause: Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, .
Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into ... Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.
What is Vistagen Therapeutics, Inc. (VTGN)'s stock price history? Over the last year, Vistagen Therapeutics, Inc.’s stock price has decreased by 7.38%. Vistagen Therapeutics, Inc. is currently ...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...
Maxim Group analyst Jason McCarthy maintained a Buy rating on Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the …In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this process is the family genogram. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical coWall Street Stock Market & Finance report, prediction for t Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen common stock, accompanying warrants to purchase up to 9,294,022 shares of Vistagen common stock (or pre-funded warrants in lieu thereof) at an exercise ... Summary of all time highs, changes and price drops for Vistagen Therapeutics; Historical stock prices; Current Share Price: US$3.65: 52 Week High: … Find the latest Vistagen Therapeutics, Inc. (VTGN) stock disc Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ... Vistagen Therapeutics, Inc. (VTGN) Stock Price, Quote, New3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NAOf the 54 institutional investors that purchased Vis Nov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. Get a real-time VistaGen Therapeutics, Inc. (VTGN) stock price quote As of June 22, 2022, the Company had 206,640,955 shares of common stock outstanding. Conference Call VistaGen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update and discuss its financial results for its fiscal year 2022 ended March 31, 2022 .Aug 13, 2014 · PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014. Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, h[Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare ConfereDec 1, 2023 · Valuation metrics show that VistaGen T SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 22, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) …Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ...